Login to Your Account

Gilead staying conservative in HCV? Or changing its tune?

By Marie Powers
Staff Writer

Thursday, February 6, 2014

As expected, Gilead Sciences Inc. reported robust revenues for the fourth quarter of 2013, up 21 percent to $3.12 billion from $2.59 billion for the same period a year earlier. Total revenues for the full year were $11.2 billion, up 15 percent compared to $9.7 billion a year earlier, on record product sales of $10.8 billion – a 15 percent year-over-year increase.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription